Drug Profile


Alternative Names: EBI 005 1; EBI 005 2; EBI-005

Latest Information Update: 18 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eleven Biotherapeutics
  • Class Anti-inflammatories; Eye disorder therapies; Peptides; Proteins
  • Mechanism of Action Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic conjunctivitis; Dry eyes

Most Recent Events

  • 16 May 2018 Eleven Biotherapeutics is now called Sesen Bio
  • 01 May 2016 Adverse events and efficacy data from preclinical studies in Dry eye disease released by Eleven Biotherapeutics (3184998; 9195137)
  • 01 May 2016 Adverse events data from preclinical studies in Allergic conjunctivitis released by Eleven Biotherapeutics (3184996; 9195137)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top